Your Messages Inbox
Most Viewed Abstracts
1. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 2. Omega-3 fatty acids for bipolar disorder 3. Is folic acid good for everyone 4. ACS Releases Guidelines for HPV Vaccination 5. Vitamin D - A review Free full text
Your Article Summary
See Latest ArticlesEffect of agalsidase alfa replacement therapy on fabry disease—related hypertrophic cardiomyopathy: A 12- to 36-month, retrospective, blinded echocardiographic pooled analysis
Clinical Therapeutics, 10/29/09
Kampmann C et al. – Treatment with agalsidase alfa for 12 or 36 months was associated with reduced LVM in these patients with Fabry disease with baseline LVH, and it appeared to stabilize LVM in these patients without baseline LVH.
Related Articles
A case of minimal change disease in a Fabry patient
Pediatric Nephrology, 11/04/09
Relevance Score: 88%
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL? for Fabry Disease with U.S. FDA
Shire, 10/22/09
Relevance Score: 88%
Genetics: Hypertrophic cardiomyopathy
Canadian Family Physician, 11/16/09
Relevance Score: 87%
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
Nephrology Dialysis Transplantation, 10/16/09
Relevance Score: 81%
Hormone replacement therapy benefits postmenopausal women
Internet Source, 10/09/09
Relevance Score: 81%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Olanzapine versus other atypical antipsychotics for schizophrenia
Cochrane Reviews, 03/19/10
Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis
Cochrane Reviews, 03/19/10
Fibrinolytic agents for peripheral arterial occlusion
Cochrane Reviews, 03/19/10
Sponsor
Article Search
Sponsor
Sponsor